Pei-Ling Chen
- Oncology top 5%
- CAR-T cell therapy research 7
- Cutaneous Melanoma Detection and Management 3
- Immunology top 5%
- Immunotherapy and Immune Responses 5
- T-cell and Retrovirus Studies 3
-
- Neurobiology and Insect Physiology Research 5
- Cancer Research top 10%
- Aging top 10%
-
- Cutaneous lymphoproliferative disorders research 7
-
- Systemic Lupus Erythematosus Research 6
-
- Nanoplatforms for cancer theranostics 3
- Co-authors
- Thomas R. ClandininJennifer A. WargoJason RoszikScott E. WoodmanHao ZhaoPadmanee SharmaChantale BernatchezP. Andrew Futreal
- Partner nations
- United StatesChinaTaiwan
In The Last Decade
Pei-Ling Chen
47 papers receiving 1.9k citations
Hit Papers
Peers
Comparison fields: 5 of 113
- Oncology 952
- Immunology 676
- Cellular and Molecular Neuroscience 291
- Cancer Research 193
- Aging 19
Countries citing papers authored by Pei-Ling Chen
This map shows the geographic impact of Pei-Ling Chen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pei-Ling Chen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pei-Ling Chen more than expected).
Fields of papers citing papers by Pei-Ling Chen
This network shows the impact of papers produced by Pei-Ling Chen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pei-Ling Chen. The network helps show where Pei-Ling Chen may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Pei-Ling Chen, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 5 | |
| 2 | 2024 | 4 | |
| 3 | 2024 | 1 | |
| 4 | 2023 | 5 | |
| 5 | 2023 | 1 | |
| 6 | 2022 | 5 | |
| 7 | 2022 | 37 | |
| 8 | 2020 | 3 | |
| 9 | 2019 | 5 | |
| 10 | 2019 | 12 | |
| 11 | 2019 | 19 | |
| 12 | 2017 | 4 | |
| 13 | 2016 | 86 | |
| 14 | Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapybreakdown → | 2016 | 913 |
| 15 | 2015 | 8 | |
| 16 | 2012 | 31 | |
| 17 | 2011 | 58 | |
| 18 | 2009 | 12 | |
| 19 | 2008 | 75 | |
| 20 | 2007 | 36 |
About Pei-Ling Chen
Pei-Ling Chen is a scholar working on Dermatology, Immunology and Oncology, having authored 47 papers that have together received 1.9k indexed citations. Recurring topics across this work include CAR-T cell therapy research (7 papers), Cutaneous lymphoproliferative disorders research (7 papers), Systemic Lupus Erythematosus Research (6 papers), Neurobiology and Insect Physiology Research (5 papers), Immunotherapy and Immune Responses (5 papers), T-cell and Retrovirus Studies (3 papers), Cutaneous Melanoma Detection and Management (3 papers) and Nanoplatforms for cancer theranostics (3 papers). The work is most often cited by research in Oncology (952 citations), Immunology (676 citations) and Cellular and Molecular Neuroscience (291 citations). Pei-Ling Chen has collaborated with scholars based in United States, China and Taiwan. Frequent co-authors include Thomas R. Clandinin, Jennifer A. Wargo, Jason Roszik, Scott E. Woodman, Hao Zhao, Padmanee Sharma, Chantale Bernatchez, P. Andrew Futreal, Jianjun Gao and Liangwen Xiong. Their work appears in journals such as Clinical Cancer Research, Cell, Modern Pathology, Neuron and Journal of Materials Science.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.